SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

Rhea-AI Summary

SciSparc (Nasdaq: SPRC)/b) reported that subsidiary NeuroThera Labs (TSXV: NTLX) has initiated a U.S. Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, to study , a proprietary cannabinoid-based candidate for adult Tourette Syndrome.

According to SciSparc, SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dosage form, aiming to reduce tics and comorbid symptoms while minimizing side effects. The randomized, double-blind, placebo-controlled, cross-over Phase IIb trial is also underway at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel.

The study builds on Phase IIa data showing an average 21% tic reduction on the Yale Global Tic Severity Scale. Adults aged 18–65 will receive SCI-110 or placebo, with primary efficacy measured by tic severity changes at weeks 12 and 26 versus baseline and safety evaluated via adverse event monitoring.

Positive

• Phase IIb trial expansion to three international sites including Yale Child Study Center
• Phase IIb design is randomized, double-blind, placebo-controlled, cross-over, enhancing data robustness
• Phase IIa study showed an average 21% tic reduction on Yale Global Tic Severity Scale
• Targeting adult Tourette Syndrome, an area with limited therapeutic options
• SCI-110 uses a proprietary combination of dronabinol and palmitoylethanolamide in a single oral dosage

Negative

• None.

Market Context

Tag-matched clinical-trial events averaged -2.17% over the provided history, adding a mixed preceden...

Analysis

Tag-matched clinical-trial events averaged -2.17% over the provided history, adding a mixed precedent to this Phase IIb site launch. The platform also records low short positioning and a resale registration; endpoint results remain the key watch.

Key Figures

Trial phase: Phase IIb Average tic reduction: 21% Patient age range: 18-65 years +1 more

4 metrics

Trial phase Phase IIb Tourette Syndrome trial for adults

Average tic reduction 21% Phase IIa study

Patient age range 18-65 years Phase IIb study population

Primary endpoint assessment Weeks 12 and 26 Change in tic severity versus baseline

Previous Clinical trial Reports

3 past events · Latest: Jul 15 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 15	Phase IIb trial initiation	Positive	+14.8%	Phase IIb site initiation for SCI-110 at Hannover Medical School in Germany.
Dec 31	Trial approval renewal	Positive	-22.7%	Israeli agency renewal approval for pediatric SCI-210 autism trial.
Aug 19	Patient enrollment	Positive	+1.4%	First five patients enrolled and dosed in SCI-210 autism trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-matched clinical announcements were mixed, with two positive reactions of 14.75% and 1.43% and one negative reaction of -22.7%, averaging -2.17%.

Key Terms

phase iib clinical trial, placebo-controlled, cross-over trial, primary efficacy endpoint, +1 more

5 terms

phase iib clinical trial medical

"initiation of NeuroThera’s Phase IIb clinical trial site at the Yale Child Study Center"

A Phase IIb clinical trial is a mid-stage study that tests whether a drug works at one or more specific doses in the patients it intends to treat, while continuing to monitor safety. Think of it as a dress rehearsal that aims to prove the treatment actually delivers the benefit seen in early tests before a large, expensive final trial. For investors, positive Phase IIb results significantly reduce scientific risk and can lift a drug’s commercial and valuation prospects, while failures often trigger sharp reassessments.

placebo-controlled medical

"a randomized, double-blind, placebo-controlled, cross-over trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

cross-over trial medical

"a randomized, double-blind, placebo-controlled, cross-over trial"

A cross-over trial is a clinical study design where each participant receives two or more treatments in a planned sequence, with a break or washout period between them, so each person acts as their own control. Like tasting two recipes one after the other to compare them directly, this design can reduce variability and need for large groups, but results hinge on timing, carryover effects, and study length—factors that affect how strong and generalizable the reported treatment effects are.

primary efficacy endpoint medical

"with the primary efficacy endpoint being the change in tic severity"

The primary efficacy endpoint is the single main result a clinical trial is designed to measure to decide whether a treatment works, chosen before the study starts. Think of it as the official scoreboard metric judges use to declare a win or loss; investors watch it because meeting or missing this pre-set goal usually drives regulatory approval odds, market expectations, and a company’s stock value.

adverse events medical

"Safety will be assessed through monitoring of adverse events"

Adverse events are any harmful or unwanted medical occurrences experienced by people using a drug, device, or undergoing a treatment, whether or not the problem is caused by the product. Think of them as complaints or breakdowns noticed during a trial or after a product is on the market; regulators record and investigate them. Investors care because clusters or serious adverse events can delay approvals, trigger costly studies or recalls, change labeling, and quickly alter a company’s revenue and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced the initiation of NeuroThera’s Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera’s proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome (“TS”) in adults.

The trial is now progressing at the Yale Child Study Center, one of the study’s key clinical sites. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in a single, innovative dosage form designed to reduce tics and associated comorbid symptoms in adults with TS while aiming to minimize side effects.

In addition to the Yale site, the Phase IIb trial is also underway at Hannover Medical School in Hanover, Germany, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.

Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera, commented: “Launching a U.S. site at the Yale Child Study Center represents a significant milestone in our global development program for SCI-110. TS remains a major unmet medical need with limited therapeutic options, particularly in adults who continue to experience persistent, severe, and often debilitating symptoms. We believe SCI-110 has the potential to introduce a novel, more effective and safer treatment approach. We are deeply committed to advancing this promising therapy and generating meaningful clinical data to support NeuroThera’s future regulatory approval.”

Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits, safety efficacy, advantages and capabilities of SCI-110 and the Company’s belief that SCI-110 has the potential to introduce a novel, more effective and safer treatment approach. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

What did SciSparc (NASDAQ: SPRC) announce about NeuroThera's Tourette Syndrome trial on August 5, 2026?

SciSparc announced that NeuroThera Labs has launched a Phase IIb trial site at the Yale Child Study Center. According to SciSparc, the study evaluates SCI-110, a cannabinoid-based candidate for adult Tourette Syndrome, as part of a multi-center, randomized, double-blind, placebo-controlled, cross-over trial.

What is SCI-110 in NeuroThera's Phase IIb Tourette trial linked to SPRC?

SCI-110 is NeuroThera’s proprietary cannabinoid-based oral drug candidate combining dronabinol and palmitoylethanolamide. According to SciSparc, it is designed to reduce tics and related comorbid symptoms in adults with Tourette Syndrome while aiming to minimize side effects through its specific combination and dosage form.

Where is the SCI-110 Phase IIb Tourette Syndrome trial for NeuroThera and SciSparc being conducted?

The Phase IIb SCI-110 trial is being conducted at Yale Child Study Center in the U.S., Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. According to SciSparc, Yale is one of the study’s key global clinical sites.

How is NeuroThera's SCI-110 Phase IIb trial for Tourette Syndrome designed?

The Phase IIb trial is randomized, double-blind, placebo-controlled and uses a cross-over design with daily oral SCI-110. According to SciSparc, adults aged 18–65 are randomized to SCI-110 or placebo, with tic severity changes assessed at weeks 12 and 26 versus baseline.

What were the Phase IIa results supporting the SCI-110 Phase IIb Tourette trial for SPRC?

The prior Phase IIa study showed an average 21% reduction in tics across participants on the Yale Global Tic Severity Scale. According to SciSparc, these safety and efficacy findings support advancing SCI-110 into the current Phase IIb Tourette Syndrome trial in adults.

What is the primary endpoint in NeuroThera's Phase IIb SCI-110 Tourette Syndrome trial?

The primary endpoint is change in tic severity measured by the Yale Global Tic Severity Scale. According to SciSparc, tic scores at weeks 12 and 26 will be compared with baseline, while safety will be evaluated through ongoing monitoring of adverse events in treated adults.